Table 1.
Characteristics of participants stratified by HIV status.
| HIV+ | HIV- | |||||
|---|---|---|---|---|---|---|
| Men | Women | All HIV+ | Men | Women | All HIV- | |
| N | 112 | 101 | 213 | 136 | 26 | 162 |
| Age*, mean (SD), years | 53.7 (7.7) | 48.8 (7.7) | 51.4 (8.0) | 59.4 (8.8) | 44.5 (10.3) | 57.0 (10.6) |
| Race*, n (%) | ||||||
| Non-black | 53 (47.3) | 16 (15.8) | 69 (32.4) | 111 (81.6) | 8 (30.8) | 119 (73.5) |
| Black | 59 (52.7) | 85 (84.2) | 144 (67.6) | 25 (18.4) | 18 (69.2) | 43 (26.5) |
| Ever AIDS, n (%) | 19 (17.0) | 40 (39.6) | 59 (27.7) | |||
| Total years spent on NRTI, median (IQR) | 22.13 (12.77, 31.29) | 19.82 (9.67, 26.56) | 21.52 (11.78, 28.28) | |||
| Total years spent on NNRTI, median (IQR) | 5.30 (0.72, 9.73) | 1.90 (0, 3.95) | 2.60 (0, 7.72) | |||
| Total years spent on PI, median (IQR) | 4.07 (0, 10.57) | 7.10 (0, 13.48) | 5.41 (0, 12.19) | |||
| Current CD4+ cell count cells/μl, mean (SD) | 615.7 (293.7) | 549.9 (260.8) | 584.0 (279.7) | |||
| Current CD8+ cell count cells/μl, mean (SD) | 887.8 (420.8) | 817.1 (425.0) | 853.8 (423.3) | |||
| Log10 (HIV RNA, copies/ml), median (IQR) | 1.6 (1.0, 1.6) | 1.7 (1.3, 2.8) | 1.6 (1.3, 1.7) | |||
| Lowest LPTA median (IQR) | 13.75 (10.00, 18.13) | 10.00 (6.25 16.25) | 12.50 (8.75, 17.50) | 13.75 (10.00, 18.75) | 7.50 (5.00, 12.50) | 12.50 (8.75, 17.50) |
| Lowest HPTA, median (IQR) | 19.38 (12.50, 31.88) | 13.75 (10.00, 21.25) | 16.25 (11.25, 26.25) | 22.50 (14.38, 34.38) | 10.63 (6.25, 13.75) | 20.00 (12.50, 33.75) |
| QOL score, median (IQR) | ||||||
| QOL index* | 77.68 (62.68, 85.57) | 84.49 (71.58, 92.58) | ||||
| Mental health* | 53.07 (44.58, 58.35) | 56.40 (50.04, 59.48) | ||||
| Physical health | 51.64 (40.54, 55.53) | 53.17 (47.82, 56.37) | ||||
HRT: Hormone Replacement Therapy; Ever AIDS: Ever diagnosed with AIDS; NRTI: Nucleoside Analog Reverse Transcriptase Inhibitor; NNRTI: Non-NRTI; PI: Protease Inhibitor; IQR = Interquartile range; log10 (HIV RNA): Current log Level of HIV RNA; SD: Standard Deviation; LPTA: Low Frequency Pure-Tone Average; HPTA: High Frequency Pure-Tone Average;
*
Comparison (HIV+ vs. HIV-) statistically significant, p-value <0.03